ATTACHMENT D: 510(k) Summary of Safety and Effectiveness

SPONSOR: Wilson-Cook Medical 4900 Bethania Station

4900 Bethania Station Road Winston-Salem, NC 27105

CONTACT/SUBMITTER: Marge Walls-Walker

Regulatory Affairs Specialist [336] -744-0157 Ex.290

DATE OF SUBMISSION: September 30, 2003

DEVICE: Tri-Tome Select Plus

Trade Name: Tri-Tome Select Plus Common Name: Sphincterotome

Classification: Unit, Electrosurgical, Endoscopic w/w/o

Accessories, Class II 21 CFR § 876.4300

PREDICATE DEVICES: Wilson-Cook Sphincterotome/Papillotome

(k901443)

Microvasive Autotome™ RX (k013153)

INTENDED USE: Wilson-Cook's Tri-Tome Select Plus

Sphincterotome is intended for cannulation of the ductal system and for sphincterotomy.

The proposed Tri-Tome Select Plus Sphincterotome is a triple-lumen

sphincterotome. It is capable of accommodating a .035" wire guide while allowing simultaneous injection of contrast media through separate

lumens.

We believe the proposed device to be substantially equivalent to currently marketed

triple-lumen transendoscopic sphincterotomes.

PERFORMANCE DATA: We believe the proposed device to be

substantially equivalent to the named predicates in terms of performance characteristics tested

and biocompatibility.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DEC 1 9 2003

Ms. Marge Walls-Walker Regulatory Affairs Specialist Wilson-Cook Medical GI Endoscopy 4900 Bethania Station Road WINSTON-SALEM NC 27105

Re: K033203

Trade/Device Name: Wilson-Cook Tri-Tome Select Plus Sphincterotome

Regulation Number: 21 CFR §876.4300

Regulation Name: Endoscopic electrosurgical unit and accessories

Regulatory Class: II Product Code: 78 KNS Dated: September 30, 2003 Received: October 2, 2003

Dear Ms. Walls-Walker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

(301) 594-4591
(301) 594-4616
(301) 594-4616
(301) 594-4654
(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Mancy C. Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number (if known): K ac	3 203		
Device Name: Wilson-Cook Tri-To	ome Select Plus Sphic	terotome	
Indications for Use:			
Used for cannulation of the ducta	l system and for sphir	ncterotomy.	•
(PLEASE DO NOT WRITE BELOW TH	HIS LINE-CONTINUE ON of CDRH, Office of Device E		DED)
a dilation of			
		•	en e
Prescription Use Only	OR	Over-the-	Counter
(Per 21 CFR § 801.109	ON .		
(1/2 1/2 la	,		
(Division Sign-Off)	hilm-		
Division of Reproductive, and Radiological Devices	Abdominal,		

510(k) Number.